sanofi
French pharmaceutical firm Sanofi has announced its stock purchase plan for employees for this year. Sanofi said its global employee shareholder plan, Action 2024, opens on June 4 to around 80,000 employees in 56 countries. From June 4 to June 24, employees will be offered shares at a subscription price of €72.87 ($79.29). For every five shares subscribed, employees will be offered one free matching share. The maximum number of Sanofi shares that may be issued under the offer is 12.6 million shares. Sanofi noted that, currently, nearly 75,000 current or former Sanofi employees are shareholders...
DPA
French pharmaceutical firm Sanofi has announced its stock purchase plan for employees for this year. Sanofi said its global employee shareholder plan, Action 2024, opens on June 4 to around 80,000 employees in 56 countries. From June 4 to June 24, employees will be offered shares at a subscription price of €72.87 ($79.29). For every five shares subscribed, employees will be offered one free matching share. The maximum number of Sanofi shares that may be issued under the offer is 12.6 million shares. Sanofi noted that, currently, nearly 75,000 current or former Sanofi employees are shareholders...
DPA International
French pharmaceutical firm Sanofi has announced its stock purchase plan for employees for this year. Sanofi said its global employee shareholder plan, Action 2024, opens on June 4 to around 80,000 employees in 56 countries. From June 4 to June 24, employees will be offered shares at a subscription price of €72.87 ($79.29). For every five shares subscribed, employees will be offered one free matching share. The maximum number of Sanofi shares that may be issued under the offer is 12.6 million shares. Sanofi noted that, currently, nearly 75,000 current or former Sanofi employees are shareholders...
DPA Breaking News
French pharmaceutical giant Sanofi is set to collaborate with OpenAI, the US developer of artificial intelligence chatbot ChatGPT, to build AI-powered software to accelerate drug development. The companies will also team up with US pharmaceutical group Formation Bio to research the potential positive impacts of AI for patients waiting for new treatments. Under the deal, the companies would bring together data, software and tuned models to develop custom, purpose-built solutions across the drug development life-cycle. Sanofi said it will leverage the partnership to provide access to proprietary...
DPA Breaking News
Sanofi, the French pharmaceutical manufacturer, said on Thursday that its first-quarter net income attributable to equity holders fell 43.2% to €1.13 billion ($1.21 billion) from last year's €2 billion. The figures are based on the International Financial Reporting Standards or IFRS. Earnings per share declined 43.1% to €0.91 from €1.60 a year ago. Business net income was €2.22 billion, compared to €2.70 billion last year. Business earnings per share were €1.78, compared to €2.16 last year. IFRS net sales grew 2.4% to €10.46 billion from last year's €10.22 billion. Sales growth was 6.7% at con...
DPA Breaking News
Tl;drLe vaccin Efluelda ne sera plus disponible en France.Sanofi impute ce retrait à un tarif de vente trop bas.Les autorités maintiennent une recommandation égale entre les vaccins.Sanofi promet de proposer son vaccin classique en remplacement.Le vaccin contre la grippe Efluelda, une prochaine absence sur le marché françaisEn raison de désaccords tarifaires, le laboratoire français Sanofi a annoncé le retrait prochain du vaccin contre la grippe Efluelda du marché français. Ce dernier n’étant pas jugé supérieur aux autres vaccins par les autorités, il ne justifie donc pas un prix plus élevé. U...
Actusante
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら